Kazuyoshi Okada

Dr. Kazuyoshi Okada


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 December 2021 in Renal Replacement Therapy
Verified
Journal Article
Open access
PDF file
KOKazuyoshi Okada
Kazuyoshi Okada
HMHiroyuki Michiwaki
Hiroyuki Michiwaki
MTManabu Tashiro
Manabu Tashiro
TITomoko Inoue
Tomoko Inoue
HSHisato Shima
Hisato Shima
SKShu Kawashima
Shu Kawashima
Background: All-cause mortality can be reduced in patients receiving European-style high-volume post-dilution online hemodiafiltration (post-OHDF) compared with hemodialysis (HD). Japanese-style high-volume pre-dilution online hemodiafiltration (pre-OHDF) can also decrease all-cause mortality. No studies have investigated survival in patients receiving Japanese-style post-OHDF, and directly compared survival between pre-OHDF and post-OHDF. This study sought to clarify these issues. Methods: We conducted this retrospective observational study at multiple facilities of our medical corporation, which have similar quality of healthcare management, from July 1, 2017 to July 1, 2020. Japanese-style OHDF included pre-OHDF and post-OHDF. Pre-OHDF and post-OHDF were each divided into high-volume and low-volume subgroups. We compared 3-year all-cause mortality and cardiovascular events between OHDF and high-flux HD using propensity score matching. In addition, we examined the effects of different modalities through comparisons between high-volume and low-volume pre-OHDF and between pre-OHDF and post-OHDF. Results: Post-OHDF was associated with significantly lower all-cause mortality (P = 0.004, log-rank test; hazard ratio [HR] 0.257, 95% confidence interval [CI] 0.094–0.701) and cardiovascular events during all 3 years (P < 0.05) compared with HD. High-volume post-OHDF was associated with lower all-cause mortality compared with hemodialysis (log-rank test P = 0.022) but low-volume post-OHDF was not. Pre-OHDF was also associated with lower all-cause mortality (P < 0.001, log-rank test; HR 0.316; 95% CI 0.212–0.472) compared with HD but was not associated with cardiovascular events. All-cause mortality did not significantly differ between post-OHDF and pre-OHDF. Conclusions: These findings suggest that Japanese-style post-OHDF may improve all-cause mortality to a level similar to that of pre-OHDF and that post-OHDF, particularly high-volume post-OHDF may reduce cardiovascular events.

8 June 2018 in BMC Research Notes
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
KMKeiko Miya
Keiko Miya
KOKazuyoshi Okada
Kazuyoshi Okada
JMJun Minakuchi
Jun Minakuchi
SKShu Kawashima
Shu Kawashima
Sucroferric oxyhydroxide, a novel iron-based phosphate-binder, has been shown to have beneficial effects in lowering serum phosphorus levels and improving renal anemia in clinical studies. Although an effect of this agent on fibroblast growth factor 23 (FGF23) has been reported in an animal study, there is little clinical data supporting this finding. This study aimed to evaluate the effect on chronic kidney disease-mineral and bone disorder, FGF23, renal anemia, iron-related parameters, adverse events of sucroferric oxyhydroxide in hemodialysis patients. Hemodialysis patients, receiving existing hyperphosphatemia drugs with insufficient benefit, were administered sucroferric oxyhydroxide with/without calcium carbonate for 16 weeks. Serum phosphorus level declined rapidly in Week 8 (p < 0.0001) and this decrease persisted until Week 16 (p < 0.0001). FGF23 decreased (p = 0.0412, Week 16), and hemoglobin increased (p < 0.0001, Week 16). Cumulative dose of erythropoiesis-stimulating agents (p = 0.0122, Week 16), and intravenous iron (p = 0.0233, Week 12) decreased. All adverse reactions were mild, and diarrhea was the most frequently observed adverse reaction (16.7%). Therefore, hyperphosphatemia treatment with sucroferric oxyhydroxide may safely improve serum phosphorus level, renal anemia, FGF23, and other factors that affect the prognosis of hemodialysis patients.

14 December 2022 in Journal of Artificial Organs
Verified
Journal Article
Open access
PDF file
KOKazuyoshi Okada
Kazuyoshi Okada
HMHiroyuki Michiwaki
Hiroyuki Michiwaki
HMHiroaki Mori
Hiroaki Mori
MTManabu Tashiro
Manabu Tashiro
TITomoko Inoue
Tomoko Inoue
SKShu Kawashima
Shu Kawashima
Online hemodiafiltration (OHDF) for renal replacement therapy has two modes: pre- (pre-OHDF) and post-dilution OHDF (post-OHDF). To elucidate the precise differences between the two modes, a clinical study was performed using the same polysulfone hemodiafilters in the same patients. Eight patients were treated with ABH™-22PA for 6 weeks: 3 weeks of pre-OHDF (with substitution volumes of 24, 36, and 48 L) and 3 weeks of post-OHDF (6, 8, and 10 L). The reduction ratios of urea, uric acid (UA), creatinine (CRE), inorganic phosphorus (iP), beta-2-microglobulin (β2-MG), and alpha-1-microglobulin (α1-MG) were evaluated. The removal amounts of β2-MG, α1-MG, and albumin were also evaluated by analyzing the spent dialysis fluids. The types and numbers of adverse events (AEs) and device malfunctions were recorded. The reduction ratios of urea, UA, CRE, iP, and β2-MG were comparable among all conditions, while that of α1-MG tended to be slightly higher in post-OHDF than in pre-OHDF. The removal amounts of α1-MG and albumin in pre-OHDF and post-OHDF were significantly greater with the maximum substitution volume than with the minimum volume. However, the selective removal indices, which were obtained by dividing the amount of α1-MG removed by the albumin level, tended to be slightly higher in pre- than in post-OHDF. No device-related AEs or device malfunctions occurred in either mode. No significant differences in inflammatory responses, evaluated by high-sensitivity C-reactive protein and interleukin-6, were observed. This study provides removal performance and safety data regarding the application of ABH-22PA for pre- and post-OHDF.

5 March 2018 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
MTManabu Tashiro
Manabu Tashiro
SYSatoshi Yamada
Satoshi Yamada
MMMotokazu Matsuura
Motokazu Matsuura
KOKazuyoshi Okada
Kazuyoshi Okada
SKShu Kawashima
Shu Kawashima
Cilostazol is an antiplatelet drug that is widely prescribed for the prevention of secondary stroke. Adverse reactions to cilostazol include headaches, palpitations, and diarrhea. Little is known about the nephrotoxicity of cilostazol, such as acute kidney injury. We report a biopsy-proven case of diffuse tubulointerstitial nephritis induced by cilostazol. A 69-year-old woman prescribed cilostazol was hospitalized for acute kidney injury. On admission, her renal function deteriorated, with an increased serum creatinine level. Urinalysis showed hematuria, proteinuria, and hyper-beta2-microglobulinuria. A renal biopsy revealed diffuse tubulointerstitial nephritis associated with IgA nephropathy, and gallium-67 scintigraphy showed uptake in the bilateral kidneys. A drug lymphocyte stimulation test for cilostazol was positive, and the patient was diagnosed with cilostazol-induced acute tubulointerstitial nephritis. Despite discontinuation of cilostazol, her renal function rapidly worsened and steroid pulse therapy was initiated, followed by oral high-dose glucocorticoid therapy. After steroid treatment, her serum creatinine level normalized in parallel with urine beta2-microglobulin. Cilostazol can induce acute tubulointerstitial nephritis.

10 April 2023 in BMC Nephrology
Verified
Journal Article
Open access
PDF file
HSHisato Shima
Hisato Shima
TDToshio Doi
Toshio Doi
TOTakuya Okamoto
Takuya Okamoto
TITomoko Inoue
Tomoko Inoue
MTManabu Tashiro
Manabu Tashiro
JMJun Minakuchi
Jun Minakuchi
Background: Crescentic immunoglobulin A (IgA) nephropathy, defined as > 50% of the glomeruli with crescents, often has a poor renal prognosis. Because of the high prevalence of pre-eclampsia in the second trimester of pregnancy, we often fail to investigate the new onset of glomerulonephritis and the aggravation of subclinical nephropathies. We report a case of nephrotic syndrome suggestive of crescentic IgA nephropathy possibly triggered by pregnancy. Case presentation: A 33-year-old multipara was referred for persistent proteinuria, hematuria, and hypoalbuminemia two months postpartum. The patient was diagnosed with proteinuria for the first time at 36 weeks of gestation. The patient was normotensive during pregnancy. Renal biopsy revealed crescentic IgA nephropathy, with cellular crescents in 80% of the glomeruli and no global sclerosis. After treatment with pulse steroids followed by high-dose oral glucocorticoids and tonsillectomy, a gradual improvement was seen in proteinuria, hematuria, and hypoalbuminemia. Conclusion: Although the precise mechanism remains unclear, pregnancy possibly triggered the new onset of crescentic IgA nephropathy or the aggravation of subclinical IgA nephropathy.

1 January 2024 in Nihon Toseki Igakkai Zasshi
Verified
Journal Article
Open access
PDF file
KOKazuyoshi Okada
Kazuyoshi Okada
YKYoshindo Kawaguchi
Yoshindo Kawaguchi
腎代替療法(kidney replacement therapy:KRT)選択の共同意思決定は,医療チームと患者との対等なパートナーシップである双方向のプロセスであるが,実際には,医療チームが話し合いを主導するため,この力関係の差により不利益を与えられている患者もいる.米国と英国では,KRT選択肢にDeciding Not to Decide(DND)が追加されている.DNDは患者に選択決定を遅らせることの身体的リスクを説明したうえで決定までの期間を提供し,患者は不安感の緩和とともに意思を決定しやすくなる.医療チームと患者・家族らが,オープンなコミュニケーションに基づいたDNDの選択肢は,患者に治療計画の柔軟性を提供し,この選択肢は関係者全員に歓迎されるであろう.KRTの情報を提供する時には,腎移植,腹膜透析,血液透析に加え,患者が自主性を高めて自ら意思を決定しやすくなるDND(選択の決定延期)の選択肢を適切な時期に提供すべきである.